Nimotop (Nimodipine)

Nimodipine blocks L‑type calcium channels in the smooth muscle of cerebral arteries. This inhibition reduces calcium entry into the cells, causing the vessels to relax and dilate, which improves cerebral blood flow and lowers the chance of vasospasm following a hemorrhagic event.

The dosage of Nimotop is determined by the prescribing clinician based on the patient’s condition, weight, and response. Healthcare professionals follow established guidelines and adjust the regimen as needed; patients should not alter the dose without medical advice.

Safety data for nimodipine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Nimotop, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nimodipine is distinguished by its high lipophilicity, which allows it to cross the blood‑brain barrier more effectively than many other calcium channel blockers. This property makes it particularly useful for cerebrovascular indications, whereas other agents are typically employed for hypertension or angina.

Nimotop should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Nimotop is taken orally, usually as a tablet, with or without food as directed by the prescriber. The medication should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

The most serious risks include severe hypotension, which can lead to dizziness or fainting, and rare but serious reactions such as myocardial infarction, hepatic dysfunction, severe allergic responses, and, in extremely uncommon cases, Stevens‑Johnson syndrome or seizures.

Patients with known hypersensitivity to nimodipine or any component of the formulation should avoid Nimotop. Caution is also advised for individuals with severe hypotension, significant liver disease, or those taking interacting medications that could amplify its blood‑pressure‑lowering effects.